Fusion is a clinical stage company focused on developing novel targeted alpha therapeutics (TAT) for the treatment of chemotherapy resistant cancers.
Our first product, FPX-01, combines the precise targeting of a human experienced antibody with Fusion’s linker technology and the alpha emitting cytotoxic isotope Actinium-225 to induce cancer cell death. FPX-01 is presently in a Phase I proof-of-concept clinical trial.
Fusion Pharmaceuticals is a spinout of the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production centre. CPDC has established an international reputation for innovation and excellence in the discovery, development and GMP manufacturing of radiopharmaceuticals for the diagnosis and treatment of disease. Fusion will leverage the CPDC’s technology and infrastructure to access new inventions and optimize its capital efficiency